Clinical Trials Logo

Clinical Trial Summary

This study is a single-center, randomized, open-label, single-dose, two-period, two-treatment crossover trial aimed at evaluating the pharmacokinetic (PK) profiles and safety of SY-5007 tablets administered orally to healthy subjects in both fasting and fed states in China.


Clinical Trial Description

The study consists of two parts: a pilot study and a formal study. The pilot study involves four healthy subjects who will receive a single dose of SY-5007 80 mg after a meal (high-fat meal) for Period 1 and on an empty stomach for Period 2, with observation and PK blood sample collection. The formal study plans to enroll 24 healthy subjects, divided into Groups A and B, each with 12 subjects, receiving a dose of 160 mg. Group A will receive the drug on an empty stomach for Period 1, followed by administration after a meal (high-fat meal) for Period 2, while Group B will follow the reverse sequence. Both groups will adopt a two-period, two-treatment crossover design with a washout period of 7 days. If the pilot study results show a significant impact of food on the PK characteristics or safety of SY-5007, subsequent trial protocols may be adjusted. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06325761
Study type Interventional
Source Shouyao Holdings (Beijing) Co. LTD
Contact Yinghui Sun, Dr
Phone 86-10-88858616
Email yhsun@centaurusbio.com
Status Not yet recruiting
Phase Phase 1
Start date April 1, 2024
Completion date May 1, 2024

See also
  Status Clinical Trial Phase
Completed NCT04932252 - A Study of A4368 in Healthy Subjects Phase 1
Completed NCT02017236 - A Food Effect Phase I Study of the Volitinib in Healthy Subjects Phase 1
Completed NCT03885778 - A Food Effect Study of Besifovir in Healthy Subjects Phase 4